Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496601 | 0.98 | NPY1R (0.47) | NPY1RNPY2RNPY4RNPY5RKMT2A | |
| SCHEMBL1496646 | 0.95 | NPY1R (0.44) | NPY1RNPY2RNPY4RNPY5RKMT2A | |
| SCHEMBL15627237 | 0.88 | SLC6A2 (0.45) | KMT2AMEN1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL20022642 | 0.86 | NPY1R (0.50) | NPY1RNPY2RNPY4RNPY5RKMT2A | |
| SCHEMBL11567061 | 0.83 | NPY1R (0.55) | NPY1RNPY2RNPY4RNPY5RKMT2A | |
| SCHEMBL11502853 | 0.80 | NPY1R (0.51) | NPY1RNPY2RNPY4RNPY5RKMT2A | |
| SCHEMBL1496621 | 0.80 | NPY1R (0.43) | NPY1RNPY2RNPY4RNPY5RKMT2A | |
| SCHEMBL15800249 | 0.80 | NPY1R (0.43) | NPY1RNPY2RNPY4RNPY5RKMT2A | |
| SCHEMBL15800248 | 0.80 | NPY1R (0.43) | NPY1RNPY2RNPY4RNPY5RKMT2A | |
| SCHEMBL15800234 | 0.80 | NPY1R (0.43) | NPY1RNPY2RNPY4RNPY5RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906667-B2 | Method for producing optically active alcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20100234629-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-7728179-B2 | Method for producing optically active alcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-01 | — | — | US | disclosed |
| EP-1380342-B1 | COMPLEX CATALYST, PROCESS FOR PRODUCING THE COMPLEX CATALYST, AND PROCESS FOR PRODUCING ALCOHOL DERIVATIVE WITH THE COMPLEX CATALYST | SUMITOMO CHEMICAL CO (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-20090012330-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1982972-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-1982973-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-6995110-B2 | Complex catalyst, process for producing the complex catalyst, and process for producing alcohol derivative with the complex catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20040077487-A1 | Complex catalyst, process for producing the complex catalyst, and process for producing alchohol derivative with the complex catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1380342-A1 | COMPLEX CATALYST, PROCESS FOR PRODUCING THE COMPLEX CATALYST, AND PROCESS FOR PRODUCING ALCOHOL DERIVATIVE WITH THE COMPLEX CATALYST | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012330-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | ADH1A, ADH1C, ADH5 | NPY1R 1888/4885NPY2R 2780/4885NPY4R 2104/4885 |
| US-20100234629-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | ADH1A, ADH1C, ADH5 | NPY1R 2052/4885NPY2R 3150/4885NPY4R 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.